Submission of Annual Report for the Financial Year 2024-25 Pursuant to Regulation 34 and other relevant provisions of the SEBI (Listing Obligations & Disclosure Requirements), 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Venmax Drugs and Pharmaceuticals Ltd has submitted its 36th Annual Report for FY 2024-25 to BSE, along with the notice for its AGM scheduled on September 27, 2025 via video conferencing. The company posted sales of Rs. 80.73 lakhs versus nil in the previous year, with total income of Rs. 186.05 lakhs (up from Rs. 19.86 lakhs). However, it slipped into a loss with a Profit/(Loss) After Tax of Rs. (1.05) lakhs versus a profit of Rs. 6.45 lakhs in FY 2023-24. No dividend has been recommended. During the year, the company made a preferential issue of 1,00,25,000 convertible equity share warrants at Rs. 20 per warrant and increased its authorized capital from Rs. 8 crore to Rs. 22 crore. AGM also seeks shareholder approval to further raise authorized capital to Rs. 60 crore, regularize Dakshita Jain as Independent Director, and appoint Kashinath Sahu & Co as Secretarial Auditors for five years.
Shareholders will see the company swing from profit to loss despite business restart, with no dividend payout. The proposed Rs. 60 crore authorized capital hike signals potential fundraising ahead, which could lead to equity dilution if shares are issued.